Saudi Arabia Pulmonary Arterial Hypertension Market Size & Outlook
Saudi Arabia pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Saudi Arabia pulmonary arterial hypertension market highlights
- The Saudi Arabia pulmonary arterial hypertension market generated a revenue of USD 121.3 million in 2023 and is expected to reach USD 186.7 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 6.4% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 121.3 million |
| Market revenue in 2030 | USD 186.7 million |
| Growth rate | 6.4% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 1.6% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Kuwait is the fastest growing regional market in Middle East & Africa and is projected to reach USD 53.1 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.24% in 2023. Horizon Databook has segmented the Saudi Arabia pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia PAH market is anticipated to grow at a lucrative growth during the forecast period. Saudi Arabia is a developing nation and is receiving help from countries such as the U.S., and Canada, to provide primary care to patients of all age groups.
The government-encouraged initiatives and development of pulmonary patient welfare legislation. The Saudi Arabian Association for Pulmonary Hypertension is taking initiatives for spreading awareness in order to curb the diseases burden.
For instance, collaborating with the Pulmonary Vascular Research Institute in 2018 had helped in introducing physicians in the North African and Middle East countries to the world experts in the field of pulmonary arterial hypertension and to the advanced development in understanding and managing PAH.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Saudi Arabia Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
